Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 61HER2-positive Breast Cancer 10Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Solid Tumor 2Prostatic Neoplasms 2Endometrial Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumors 1Solid Cancers 1Solid Cancer 1Resectable HER2-positive Breast Cancer 1Recurrence 1Patient Preference 1Neoplasms, Unknown Primary 1Lung Neoplasms 1Liver Neoplasms 1Inflammatory Breast Neoplasms 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1cabazitaxel 1XRP6258 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Cancer × pertuzumab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡